Implementation of Osteoporosis Screening Guidelines in Prostate Cancer Patients on Androgen Ablation

Journal of Clinical Densitometry

Volumn 12, Issue 3, 2009, Pages 287-291

  Van Tongeren, Lindsay S ^a   Duncan, Graeme G ^a   Kendler, David L ^b   Pai, Howard ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen ablation therapy; bone mineral density; clinical guidelines implementation; osteoporosis screening; prostate cancer

Indexed keywords

ANTIANDROGEN;

ADULT; AGED; ARTICLE; BONE DENSITY; CANADA; CANCER PATIENT; HUMAN; MALE; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RISK ASSESSMENT;

ABSORPTIOMETRY, PHOTON; ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BRITISH COLUMBIA; COHORT STUDIES; GONADOTROPIN-RELEASING HORMONE; GUIDELINE ADHERENCE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 67651233518     PISSN: 10946950     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocd.2009.05.001     Document Type: Article

References (29)

1. Lu-Yao G.L., Albertson P.C., Moore D.F., et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300 (2008) 173-181
2. Shahinian V.B., Kuo Y., Freeman J.L., et al. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103 (2005) 1615-1624
3. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26 (2008) 15
4. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360 (2002) 103-106
5. Vanderschueren D., Gaytant J., Boonen S., and Venken K. Androgens and bone. Curr Opin Endocrinol Diabetes Obes 15 (2008) 250-254
6. Falahati-Nini A., Riggs B.L., Atkinson E.J., et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106 (2000) 1553-1560
7. Wei J.T., Gross M., Jaffe C.A., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54 (1999) 607-611
8. Malcolm J.B., Derweesh I.H., Kincade M.C., et al. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Can J Urol 14 (2007) 3551-3559
9. Morote J., Morin J.P., Orsola A., et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69 (2007) 500-504
10. Shahinian V.B., Kuo Y., Jean L., et al. Risk of fracture after androgen deprivation for prostate cancer. NEJM 352 (2005) 154-164
11. Melton III L.J., Alothman K.I., Khosla S., et al. Fracture risk following bilateral orchiectomy. J Urol 169 (2003) 1747-1750
12. Jackson J.A., Riggs M.W., and Spiekerman A.M. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci 304 (1992) 4-8
13. Basaria S., Lieb II J., Tang A.M., et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol 56 (2002) 779-786
14. Kiratli B.J., Srinivas S., Perkash I., and Terris M.K. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57 (2001) 127-132
15. Morote J., Martinez E., Trilla E., et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 44 (2003) 661-665
16. Oefelein M.G., Ricchuiti V., Conrad W., et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166 (2001) 1724-1728
17. Townsend M.F., Sanders W.H., Northway R.O., and Graham Jr. S.D. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79 (1997) 545-550
18. López A.M., Pena M.A., Hernández R., et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 16 (2005) 707-711
19. Abrahamsen B., Nielsen M.F., Eskildsen P., et al. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 100 (2007) 749-754
20. Smith M.R., Lee W.C., Brandman J., et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23 (2005) 7897-7903
21. Duncan G.G., Corbett T., Lukka H., et al. GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol 13 (2006) 2962-2966
22. Francke A.L., Smit M.C., de Veer A.J.E., and Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak 8 (2008) 38
23. Woolf S.H., Grol R., Hutchinson A., et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ 318 (1999) 527-530
24. Grol R., and Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 362 (2003) 1225-1230
25. Brown J.P., Josse R.G., and The Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 10 Suppl (2002) S1-S34
26. Qaseem A., Snow V., Shekelle P., et al. Screening for osteoporosis in men: a clinical practice guideline from the American college of physicians. Ann Intern Med 148 (2008) 680-684
27. Jaglal S.B., McIsaac W.J., Hawker G., et al. Patterns of use of the bone mineral density test in Ontario, 1992-1998. CMAJ 163 (2000) 1139-1143
28. Vanasse A., Dagenais P., Niyonsenga T., et al. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord 6 (2005) 1471-2474
29. Rideout R., and Hawker G.A. Use of bone densitometry by Ontario family physicians. Osteoporos Int 11 (2000) 393-399